Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Activating mutations in epidermal growth factor receptor (EGFR) drive lung cancer.
• Tyrosine kinase inhibitors (TKIs) initially shrink tumors but resistance develops, often due to secondary mutations like T790M and C797S.
• These resistance mutations render current EGFR TKIs ineffective.

Purpose of the Study:

• To discover and characterize BI-4020, a novel noncovalent TKI.
• To evaluate BI-4020's efficacy against EGFR variants with resistance mutations.
• To assess BI-4020's potential in overcoming TKI resistance in lung cancer.

Main Methods:

• Discovery of a selective benzimidazole scaffold.
• Macrocyclization to rigidify the molecule and enhance potency.
• In vitro and in vivo testing in EGFR-mutant lung cancer models, including xenografts with EGFR^del19/T790M/C797S mutations.

Main Results:

• BI-4020 is a noncovalent TKI that spares wild-type EGFR.
• BI-4020 potently inhibits EGFR variants with T790M and C797S resistance mutations.
• BI-4020 demonstrated significant tumor regressions in a cross-resistant EGFR^del19/T790M/C797S xenograft model.

Conclusions:

• BI-4020 represents a promising therapeutic strategy against EGFR-mutant lung cancers resistant to existing TKIs.
• The macrocyclic structure and specific design of BI-4020 enable potent inhibition of challenging EGFR mutations.
• Further development of BI-4020 could offer a new treatment option for patients with advanced lung cancer.